ibs.GRANADA researchers generate monoclonal antibodies that will serve to improve research on different diseases
The international company Cancer Research Technology Limited will offer these antibodies produced by hybridomas to the scientific community
research groups A08-Immune Response and Cancer y MP04-Immunogenetics, Systemic and Skin Diseases from the Biosanitary Research Institute of Granada (ibs.GRANADA) developed monoclonal antibodies using hybridoma technology that can be applied in the diagnosis of leukemias and lymphomas, as well as improving the immunological analysis of human body tissues.
Monoclonal antibodies are in vitro-derived proteins designed to selectively bind to a specific molecule. They are made in the laboratory from immune cells that are fused with myeloma cells to create hybridomas. Hybridomas are hybrid cells that have the ability to produce specific monoclonal antibodies and can be cloned to produce large amounts of uniform, purified monoclonal antibodies. Monoclonal antibodies are valuable research tools, allowing the identification and characterization of proteins, detection of diseases, development of new therapies, and customization of treatments for specific diseases.
These antibodies were created in the Clinical Analysis Service of the Virgen de las Nieves University Hospital in Granada and will be exploited by the company Cancer Research Technology Limited, thanks to the commercial exploitation license agreement made with the Andalusian Health Service of the Junta de Andalusia. The purpose of this commercial exploitation is for the research use of these monoclonal antibodies engineered by these two teams of Granada scientists belonging to the ibs.GRANADA.
The process of identification and negotiation of the exploitation license has been carried out by the Innovation and Technology Transfer Unit of the ibs.GRANADA and the Technology Transfer Office of the Andalusian Public Health System.
The antibodies were accredited in the International Workshops that defined the first groups of lymphocyte differentiation. The hybridomas were obtained with financing from Projects of the Carlos III Health Institute and the Ministry of Health.
About the research groups
The research groupA08-Immune Response and Cancer” from ibs.GRANADA whose lead researcher has been Federico Garrido and currently directed by Francisco Ruiz-Cabello Osuna, is involved in the analysis of the immune response in cancer, the role of infiltrating leukocytes and the immunophenotypic characteristics of the cells tumors. The research group has identified the main escape mechanisms used by tumors (kidney, bladder, prostate and colon cancer) to evade the immune response. In particular, it focuses on those mechanisms that prevent antigenic recognition by immune cytotoxic effectors. The most relevant aspects that these defects have in various immunotherapy protocols and the possible correction, through gene therapy procedures, have been evaluated. The group collaborates with various European and American centers working on the design of cancer vaccines.
More information about the group: https://www.ibsgranada.es/grupos-de-investigacion/a08-respuesta-inmune-y-cancer/
The research groupMP04-Immunogenetics Systemic and Cutaneous Diseases” Led by Miguel Ángel López Nevot, it focuses on the study of immunogenic markers and their relationship with the immunopathological mechanisms of autoimmune diseases with special interest in inflammatory bowel disease. In a second line of work related to Cutaneous Oncology, they analyze the effect of genetic elements on the predisposition, development and evolution of melanoma.
More information about the group: https://www.ibsgranada.es/grupos-de-investigacion/mp04-inmunogenetica-enfermedades-sistemicas-y-cutaneas/
